towermansion https://blog.hatena.ne.jp/towermansion/ 勉強用 https://towermansion.hatenablog.com/ lung cancer～NSCLC～StageIV～Driver+ N Engl J Med. 2024 Jan 11;390(2):118-131. BACKGROUNDThe early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for thetreatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumoractivity, but resistance develops in tumors, and intracranial activity is subopt… 190 <iframe src="https://hatenablog-parts.com/embed?url=https%3A%2F%2Ftowermansion.hatenablog.com%2Fentry%2F2024%2F02%2F27%2F032817" title="Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer - 勉強用" class="embed-card embed-blogcard" scrolling="no" frameborder="0" style="display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;"></iframe> Hatena Blog https://hatena.blog 2024-02-27 03:28:17 rich https://towermansion.hatenablog.com/entry/2024/02/27/032817 1.0 100%